MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2024 International Congress

    ilex Paraguariensis (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.

    J. Ferrario, H. Hauche, L. Tschopp, T. Eidelman, M. Bordone (Buenos Aires, Argentina)

    Objective: To investigate the molecular pathways regulated by yerba mate [YM] extract and its main active compounds in a neuronal cell line as a cue…
  • 2024 International Congress

    Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD

    T. Rodriguez, R. Smeyne, M. Smeyne (Philadelphia, USA)

    Objective: The goal of this study is to characterize microvascular changes in the SNpc in response to a neuroprotective bout of exercise. Background: Parkinson’s disease…
  • 2024 International Congress

    Time-Restricted Eating in Huntington’s Disease: Review of the Literature and a Proposed Clinical Trial

    R. Wells, L. Neilson, A. Mchill, A. Hiller (Portland, USA)

    Objective: Review recent literature on time-restricted eating (TRE) in Huntington’s disease (HD) and outline our protocol for an upcoming clinical trial designed to assess the…
  • 2023 International Congress

    Neuroprotective properties of arylpiperazine-sulphonamides in an in vitro model of Parkinson’s disease

    A. Kingslake, V. Soskic, M. Iravani (Hatfield, United Kingdom)

    Objective: To investigate the neuroprotective effects of novel arylpiperazine compounds as measured by viability of SH-SY5Y cells in vitro. Background: Parkinson’s disease (PD) is a…
  • 2023 International Congress

    Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced- Parkinson’s disease model

    SHI. Kartik (Lucknow, India)

    Objective: The current investigation aimed to investigate the neuroprotective effect of niclosamide (NI) on autophagy and neuroinflammatory pathways in Parkinson’s disease (PD). Background: Autophagy dysregulation…
  • 2023 International Congress

    Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model

    D. Khatri, S. Shah, K. Tryphena (Hyderabad, India)

    Objective: To explore the antioxidant and anti-inflammatory role of Carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model Background: NLRP3 inflammasome mediated neuroinflammation is…
  • 2023 International Congress

    Quercetin hinders Glial Activation to Alleviate the Cadmium Induced Dopaminergic Alteration via TNFα mediated CAMKIIα/ERK activation

    R. Shukla, V. Khanna, R. Gupta (bahraich, India)

    Objective: The present study has therefore been carried out identify neuroprotective role of quercetin in alleviating the cadmium induced dopaminergic dysfunctions via glial mediated deactivation…
  • 2023 International Congress

    Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model

    R. Wells, A. Azzam, A. Hiller, M. Sardinia (Portland, USA)

    Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…
  • 2023 International Congress

    Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease

    R. Kumar, A. Kanojia (Darbhanga, India)

    Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action ofRT in experimental models of PD. Background: The…
  • 2023 International Congress

    Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease

    M. Werner, R. Rush, T. Kelly, S. Singh, S. Kruger, C. Olanow, A. Mcgarry (Atlanta, USA)

    Objective: To evaluate the therapeutic potential of the selective, brain penetrant c-Abl inhibitor IkT-148009 in mouse models of progressive PD and the safety and tolerability…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Crack Dancing: An Uncommon Drug-Induced Chorea
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An atypical and interesting feature of Parkinson´s disease
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley